Current Value
$465.101 Year Return
Current Value
$465.101 Year Return
SeekingAlpha
Explore June's rising CPI inflation, the Fed's likely rate stance, and market opportunities in non-cyclicals and high-margin sectors amidst inflation pressures.
SeekingAlpha
Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.
Yahoo
Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
Yahoo
As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by companies like Nvidia. In this dynamic environment, identifying high-growth tech stocks involves looking at those that can leverage current trends such as AI advancements and strategic partnerships to sustain their momentum in a competitive landscape.
Yahoo
Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement agreement for the cystic fibrosis treatment ALYFTREK underscores VRTX's therapeutic expansion and patient outreach, counteracting any potential negative market effects from removing the stock from various value indices like the Russell 1000. Positive news on other fronts like long-term data for...
Yahoo
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis. The approval comes on the basis of ALYFTREK demonstrating non-inferiority compared to the existing treatment, KAFTRIO, in terms of lung function measurement. “Deutivacaftor/tezacaftor/vanzacaftor […]
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VIV | -0.03% | $18.00B | +28.81% | 0.69% |
| ZCMD | -0.07% | $28.79M | -11.91% | 0.00% |
| AQB | 0.16% | $3.12M | -54.47% | 0.00% |
| CVM | 0.17% | $19.32M | -90.76% | 0.00% |
| BYRN | 0.21% | $511.06M | +115.41% | 0.00% |
| CEG | -0.28% | $102.17B | +53.13% | 0.46% |
| SATS | -0.32% | $8.60B | +50.08% | 0.00% |
| HDSN | 0.32% | $353.06M | -7.20% | 0.00% |
| CRMD | -0.33% | $845.52M | +131.84% | 0.00% |
| RLX | 0.34% | $2.15B | +33.33% | 0.43% |
| SRRK | -0.43% | $3.66B | +319.00% | 0.00% |
| VHC | 0.43% | $74.47M | +193.32% | 0.00% |
| GME | -0.50% | $10.60B | -12.22% | 0.00% |
| SOC | 0.50% | $2.23B | +38.21% | 0.00% |
| LQDT | -0.51% | $754.29M | +19.37% | 0.00% |
| OSCR | 0.62% | $3.84B | -5.75% | 0.00% |
| ULS | 0.66% | $14.53B | +65.13% | 0.71% |
| AMPY | 0.77% | $135.53M | -53.72% | 0.00% |
| VRCA | -0.77% | $75.38M | -90.26% | 0.00% |
| OCFT | -0.86% | $277.06M | +298.41% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AIFU | -18.20% | $17.40M | +87.81% | 0.00% |
| SHCO | -17.02% | $1.37B | +16.31% | 0.00% |
| CPSH | -12.29% | $36.61M | +48.24% | 0.00% |
| MQ | -11.92% | $2.74B | +7.14% | 0.00% |
| CNK | -11.63% | $3.43B | +40.21% | 0.54% |
| DHC | -8.09% | $938.47M | +16.12% | 1.03% |
| LMB | -7.98% | $1.74B | +132.77% | 0.00% |
| MNOV | -7.85% | $62.78M | -9.86% | 0.00% |
| QNRX | -7.77% | $5.32M | -60.47% | 0.00% |
| EVGO | -6.97% | $470.93M | -12.47% | 0.00% |
| FARO | -6.75% | $848.40M | +153.29% | 0.00% |
| TIMB | -6.55% | $9.03B | +23.45% | 2.18% |
| STG | -6.42% | $56.15M | +27.66% | 0.00% |
| USM | -6.26% | $5.92B | +21.07% | 0.00% |
| AORT | -6.23% | $1.35B | +14.45% | 0.00% |
| BTCT | -5.12% | $29.39M | +101.55% | 0.00% |
| MESO | -5.08% | $1.43B | +46.01% | 0.00% |
| HUSA | -4.70% | $20.46M | -9.15% | 0.00% |
| K | -4.66% | $27.64B | +41.46% | 2.87% |
| TDS | -4.50% | $4.54B | +86.53% | 0.41% |
Double maintains 13 strategies that include VRTX - Vertex Pharmaceuticals, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KRYS | 50.22% | $4.35B | -27.65% | 0.00% |
| AMGN | 43.07% | $159.71B | -10.03% | 3.12% |
| IDYA | 41.89% | $1.98B | -45.39% | 0.00% |
| ABBV | 41.53% | $338.30B | +13.98% | 3.37% |
| PFE | 41.20% | $144.12B | -12.89% | 6.69% |
| CSGP | 40.74% | $36.13B | +12.67% | 0.00% |
| REGN | 40.73% | $61.60B | -47.27% | 0.15% |
| RGNX | 40.36% | $438.38M | -32.40% | 0.00% |
| SNDX | 40.07% | $847.57M | -59.60% | 0.00% |
| TECH | 40.03% | $8.25B | -31.85% | 0.61% |
| AVY | 39.44% | $14.11B | -17.55% | 1.98% |
| PRAA | 38.72% | $628.99M | -25.64% | 0.00% |
| MFA | 38.64% | $954.67M | -18.78% | 15.16% |
| ROIV | 38.32% | $7.91B | +1.13% | 0.00% |
| NSA | 38.01% | $2.50B | -25.82% | 6.93% |
| BIIB | 37.99% | $19.50B | -39.93% | 0.00% |
| CIGI | 37.55% | $6.86B | +8.37% | 0.22% |
| IMNM | 37.42% | $740.47M | -39.90% | 0.00% |
| GSK | 37.25% | $77.41B | -0.98% | 4.17% |
| LOW | 37.16% | $124.64B | -4.21% | 2.06% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -34.95% | $198.83M | 0.85% |
| VIXM | -31.76% | $23.12M | 0.85% |
| TAIL | -20.67% | $94.79M | 0.59% |
| BTAL | -18.20% | $310.74M | 1.43% |
| CLIP | -14.62% | $1.51B | 0.07% |
| IVOL | -11.37% | $342.76M | 1.02% |
| TBLL | -8.48% | $2.11B | 0.08% |
| XHLF | -8.31% | $1.75B | 0.03% |
| TPMN | -8.14% | $31.00M | 0.65% |
| BILS | -7.35% | $3.81B | 0.1356% |
| UNG | -7.07% | $422.40M | 1.06% |
| GBIL | -5.66% | $6.37B | 0.12% |
| USDU | -4.69% | $130.22M | 0.5% |
| ULST | -4.58% | $590.76M | 0.2% |
| BIL | -4.37% | $41.80B | 0.1356% |
| USO | -4.37% | $1.13B | 0.6% |
| BNO | -4.30% | $111.07M | 1% |
| OILK | -3.75% | $74.24M | 0.69% |
| DBE | -3.60% | $54.90M | 0.77% |
| KCCA | -3.38% | $109.69M | 0.87% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BBH | 62.27% | $339.74M | 0.35% |
| IBB | 59.94% | $5.48B | 0.45% |
| FBT | 53.16% | $1.03B | 0.54% |
| VHT | 52.76% | $15.33B | 0.09% |
| XBI | 52.38% | $5.07B | 0.35% |
| IXJ | 52.02% | $3.76B | 0.41% |
| FHLC | 51.95% | $2.43B | 0.084% |
| IYH | 51.71% | $2.73B | 0.39% |
| XLV | 51.53% | $33.63B | 0.09% |
| PBE | 49.52% | $229.54M | 0.58% |
| PPH | 47.52% | $537.40M | 0.36% |
| PINK | 47.18% | $130.53M | 0.5% |
| RSPH | 46.30% | $718.84M | 0.4% |
| IHE | 45.58% | $557.84M | 0.39% |
| FXH | 45.35% | $880.12M | 0.62% |
| GNOM | 45.14% | $44.39M | 0.5% |
| XPH | 43.44% | $168.46M | 0.35% |
| FDLO | 40.41% | $1.22B | 0.16% |
| OUSA | 40.28% | $816.16M | 0.48% |
| USMV | 40.06% | $23.52B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GLDM | 0.09% | $16.11B | 0.1% |
| SPTS | 0.10% | $5.78B | 0.03% |
| COMT | -0.10% | $619.71M | 0.48% |
| CANE | -0.10% | $11.33M | 0.29% |
| GSG | -0.14% | $1.02B | 0.75% |
| BAR | 0.20% | $1.13B | 0.1749% |
| KBA | -0.23% | $179.26M | 0.56% |
| DBC | 0.24% | $1.27B | 0.87% |
| KRBN | 0.26% | $160.65M | 0.85% |
| URNM | -0.26% | $1.62B | 0.75% |
| UGA | -0.32% | $76.42M | 0.97% |
| PDBC | 0.38% | $4.59B | 0.59% |
| SGOL | 0.40% | $5.27B | 0.17% |
| IBTH | 0.44% | $1.62B | 0.07% |
| BSCP | 0.52% | $3.25B | 0.1% |
| TFLO | -0.54% | $6.74B | 0.15% |
| IAU | 0.55% | $47.75B | 0.25% |
| GLD | 0.57% | $102.12B | 0.4% |
| AAAU | 0.62% | $1.57B | 0.18% |
| STOT | 0.70% | $254.18M | 0.45% |
